Full Press Release Details
Media
• November 10, 2025
IRWD Positive Sentiment
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
Key Takeaway: Ironwood Pharmaceuticals has announced strong financial results for the third quarter of 2025, demonstrating significant growth. The company has also raised its financial guidance for the full year 2025, indicating confidence in its future performance. This positive outlook reflects the company's successful strategies and market position.
Price reaction · baseline $1.92 (2025-11-07 close) · clean, no other IRWD news in the window
day 0 close
+31.8%
day 1
+50.5%
day 3 · peak
+75.5%
Market Sentiment Analysis
POSITIVE FACTORS
- Strong third quarter results reported.
- Increased financial guidance for the full year 2025.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What were Ironwood's Q3 2025 results?
Ironwood Pharmaceuticals reported strong financial results for Q3 2025.
Did Ironwood raise its financial guidance?
Yes, Ironwood raised its financial guidance for the full year 2025.